All lobbying filings

Emergent Strategies

Emergent Strategies filed a Q1 report for Genbiopro, Inc. on April 20, 2026.

Lobbying for Genbiopro, Inc. · Generic Pharmaceutical Manufacturer

As filed: EMERGENT STRATEGIES for GENBIOPRO, INC.

All filings by Emergent Strategies · Everything Genbiopro, Inc. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Money reported

None

Registrations and no-activity reports carry no figure.

Client based in

Nevada

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Pharmacy

FDA Approval of generic mifepristone and relate Risk Evaluation Mitigation Strategies (REMS)

Veterans

VA rule making on providing abortion services to veterans

Health Issues

Issues related to medication abortion; Issues related to abortion access

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.